Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 107

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Lonza Group Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Capsugel Acquires FlexTab Technology From GlaxoSmithKline 19
Venture Financing 20
Odyssey Thera Raises US$3 Million In Venture Financing 20
Private Equity 21
Kainos Capital Acquires InterHealth Nutraceuticals 21
Kohlberg Kravis Completes Acquisition Of Capsugel From Pfizer 22
Partnerships 24
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 24
Capsugel Enters into Agreement with Pulmatrix 25
Lonza Enters into Agreement with Kodiak Sciences 26
CiMaas Enters into Agreement with PharmaCell 27
Lonza Partners with Octane Biotech 28
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29
Lonza and AMYRA Biotech Enter into Agreement 30
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31
Catalent Pharma Solutions Enters Into Agreement With Bend Research 32
CSIRO Enters Into Co-Development Agreement With Lonza 33
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34
Lonza Enters Into Co-Marketing Agreement With Lipogen For Phosphatidylserine-Based Formulas 35
Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 36
Bend Research Enters Into An Agreement With Xcelience 37
Critical Outcome Technologies and Xcelience Enter into Agreement 38
Athera Biotechnologies Enters Into Co-Development Agreement With Lonza 39
Licensing Agreements 40
Xbiotech Enters into Licensing Agreement with Lonza Sales 40
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 41
Pierre Fabre Enters into Licensing Agreement with Lonza 43
Pierre Fabre Enters into Licensing Agreement with Lonza 44
CytoDyn Enters into Licensing Agreement with Lonza Sales 45
Lonza Enters into Licensing Agreement with arGEN-X 46
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 47
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 49
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 50
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 51
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 52
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 53
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 54
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 55
Bend Research Enters Into Licensing Agreement With Merck 56
Oxford BioTherapeutics Enters Into Licensing Agreement With Lonza 57
Enzymicals Enters Into Licensing Agreement With Lonza For (R)-selective Transaminases 58
Lonza Enters Into License Agreement With ORGANOBALANCE 59
Equity Offering 60
Lonza Raise USD2.24 Billion in Rights Offering of Shares 60
Lonza Raises USD871 Million in Private Placement of Shares 61
Lonza Group Completes IPO Of Common Stock On Singapore Exchange 62
Debt Offering 63
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 63
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 64
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 65
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 66
Lonza Completes Public Offering Of Bonds Due 2015 For US$266 Million 67
Lonza Completes Public Offering Of Bonds Due 2018 For US$155 Million 68
Asset Transactions 69
PolyPeptide to Acquire Peptides Business and Operations in Braine, Belgium from Lonza 69
Acquisition 70
Lonza Group Acquires micromacinazione from Cross 70
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 71
Lonza Group Acquires PharmaCell 73
Lonza Acquires HansaBioMed Life Sciences 74
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 75
Lonza May Acquire Catalent 76
Capsugel Acquires Xcelience 77
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 78
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 79
Capsugel Completes Acquisition Of Bend Research, Drug Delivery Technologies Company 80
Capsugel Belgium Acquires Encap Drug Delivery 81
Lonza Group Ltd - Key Competitors 82
Lonza Group Ltd - Key Employees 83
Lonza Group Ltd - Locations And Subsidiaries 84
Head Office 84
Other Locations & Subsidiaries 84
Joint Venture 87
Recent Developments 88
Strategy And Business Planning 88
Aug 24, 2017: Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms 88
Feb 02, 2016: Lonza to Build Capabilities for Drug Product Development Services, Enabling One-Stop-Shop Solutions for Customers 89
Financial Announcements 90
Oct 26, 2017: Lonza Reports a Strong Third Quarter and Capsugel Integration on Track 90
Jul 26, 2017: Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid-Term Growth 92
Jan 25, 2017: Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech 94
Apr 26, 2016: Lonza Reports Record First Quarter 96
Jan 27, 2016: Lonza Reports Strong Sales and Profit Growth in 2015 97
Corporate Communications 99
Jun 27, 2017: Lonza's CHRO Elected to Board of Advance Women in Swiss Business 99
Jan 25, 2017: Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 100
May 10, 2016: Rodolfo Savitzky appointed as new CFO for Lonza to succeed Toralf Haag who was appointed as CFO of the Voith in Germany 101
Mar 23, 2016: Lonza Consumer Care Announces Appointment of Dr. Russell Elliott PhD as Director of Skin Care Technology 102
Product News 103
Nov 08, 2017: Lonza Launches XS Pichia 2.0 Expression and Manufacturing Platform for Development of Next Generation Therapeutics 103
Sep 07, 2016: Lonza Releases Second-Generation Immunogenicity Assessment and Optimization Platform for Development of Therapeutic Proteins, Vaccines and Cell Therapies 104
Mar 30, 2016: Lonza Launches Sentinel APART Server-Based Platform Designed to Help Improve the Quality and Safety of Therapeutic Antibodies 105
Other Significant Developments 106
May 17, 2016: Lonza CytoSMART Lab Free-Trial Initiative Launched 106
Appendix 107
Methodology 107
About GlobalData 107
Contact Us 107
Disclaimer 107

List of Tables
Lonza Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Lonza Group Ltd, Deals By Therapy Area, 2011 to YTD 2017 11
Lonza Group Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Capsugel Acquires FlexTab Technology From GlaxoSmithKline 19
Odyssey Thera Raises US$3 Million In Venture Financing 20
Kainos Capital Acquires InterHealth Nutraceuticals 21
Kohlberg Kravis Completes Acquisition Of Capsugel From Pfizer 22
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 24
Capsugel Enters into Agreement with Pulmatrix 25
Lonza Enters into Agreement with Kodiak Sciences 26
CiMaas Enters into Agreement with PharmaCell 27
Lonza Partners with Octane Biotech 28
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29
Lonza and AMYRA Biotech Enter into Agreement 30
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31
Catalent Pharma Solutions Enters Into Agreement With Bend Research 32
CSIRO Enters Into Co-Development Agreement With Lonza 33
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34
Lonza Enters Into Co-Marketing Agreement With Lipogen For Phosphatidylserine-Based Formulas 35
Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 36
Bend Research Enters Into An Agreement With Xcelience 37
Critical Outcome Technologies and Xcelience Enter into Agreement 38
Athera Biotechnologies Enters Into Co-Development Agreement With Lonza 39
Xbiotech Enters into Licensing Agreement with Lonza Sales 40
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 41
Pierre Fabre Enters into Licensing Agreement with Lonza 43
Pierre Fabre Enters into Licensing Agreement with Lonza 44
CytoDyn Enters into Licensing Agreement with Lonza Sales 45
Lonza Enters into Licensing Agreement with arGEN-X 46
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 47
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 49
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 50
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 51
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 52
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 53
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 54
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 55
Bend Research Enters Into Licensing Agreement With Merck 56
Oxford BioTherapeutics Enters Into Licensing Agreement With Lonza 57
Enzymicals Enters Into Licensing Agreement With Lonza For (R)-selective Transaminases 58
Lonza Enters Into License Agreement With ORGANOBALANCE 59
Lonza Raise USD2.24 Billion in Rights Offering of Shares 60
Lonza Raises USD871 Million in Private Placement of Shares 61
Lonza Group Completes IPO Of Common Stock On Singapore Exchange 62
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 63
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 64
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 65
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 66
Lonza Completes Public Offering Of Bonds Due 2015 For US$266 Million 67
Lonza Completes Public Offering Of Bonds Due 2018 For US$155 Million 68
PolyPeptide to Acquire Peptides Business and Operations in Braine, Belgium from Lonza 69
Lonza Group Acquires micromacinazione from Cross 70
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 71
Lonza Group Acquires PharmaCell 73
Lonza Acquires HansaBioMed Life Sciences 74
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 75
Lonza May Acquire Catalent 76
Capsugel Acquires Xcelience 77
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 78
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 79
Capsugel Completes Acquisition Of Bend Research, Drug Delivery Technologies Company 80
Capsugel Belgium Acquires Encap Drug Delivery 81
Lonza Group Ltd, Key Competitors 82
Lonza Group Ltd, Key Employees 83
Lonza Group Ltd, Subsidiaries 84
Lonza Group Ltd, Joint Venture 87

List of Figures
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Lonza Group Ltd, Medical Devices Deals, 2011 to YTD 2017 12

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027